This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Severe COVID-19 is characterised by inflammation and immature myeloid cells early in disease progression (preprint)
medrxiv; 2021.
Preprint
in English
| medRxiv | ID: ppzbmed-10.1101.2021.09.01.21262953
ABSTRACT
SARS-CoV-2 infection causes a wide spectrum of disease severity. Immune changes associated with severe disease include pro-inflammatory cytokine production and expansion of immature myeloid populations. The relative importance of the immunological changes in driving progression to severe disease remain poorly understood. We aimed to identify and rank clinical and immunological features associated with progression to severe COVID-19. We sought to use tests available in an on-site diagnostic hospital laboratory to identify an immunological signature for severe disease development which could be detected prior to peak severity thereby allowing initiation of therapeutic interventions. We used univariate and multivariate analysis, including unbiased machine learning, to investigate the relationships between clinical and demographic characteristics, inflammatory markers, and leukocyte immunophenotypes with progression to severe disease in 108 patients and to rank these in importance. A combination of four features (elevated levels of interleukin-6 and C-reactive protein, coupled with reduced monocyte HLA-DR expression and reduced neutrophil CD10 expression), were strongly predictive of severe disease with an average prediction score of 0.925. HighlightsO_LISevere COVID-19 can be predicted by a combination of emergency myelopoiesis (CD10-neutrophils and HLA DR-monocytes) and inflammation (raised IL-6 and CRP) C_LIO_LIThese changes can be identified from tests carried out prior to peak illness severity in a diagnostic laboratory C_LIO_LIThis predictive model was derived from a cohort of patients with a wide range of ages, frailty and COVID-19 severity C_LI Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=191 HEIGHT=200 SRC="FIGDIR/small/21262953v1_ufig1.gif" ALT="Figure 1"> View larger version (37K) org.highwire.dtl.DTLVardef@16c6947org.highwire.dtl.DTLVardef@73ba2corg.highwire.dtl.DTLVardef@1c3dd82org.highwire.dtl.DTLVardef@3a48f_HPS_FORMAT_FIGEXP M_FIG C_FIG
Full text:
Available
Collection:
Preprints
Database:
medRxiv
Main subject:
COVID-19
/
Inflammation
Language:
English
Year:
2021
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS